BioAtla公司与GATC Health共同宣布，双方已达成一项价值4000万美元的特殊目的载体（SPV）交易。该资金将专项用于推动Ozuriftamab Vedotin（简称Oz-V）进入针对二线及以上治疗（2L+）口咽鳞状细胞癌（OPSCC）的注册性临床试验阶段。
此次合作标志着Oz-V在头颈癌治疗领域迈出关键一步。通过设立特殊目的载体，双方旨在高效配置资源，加速该创新疗法的临床开发进程，为复发或转移性口咽鳞状细胞癌患者提供新的治疗希望。
注册性临床试验的启动将重点评估Oz-V在经治患者群体中的疗效与安全性。若试验结果达到预期，该药物有望为口腔肿瘤治疗领域带来突破性进展。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.